Eclipsor
Provider 
Founded 2006
Sells To Businesses
Pricing Model Pre-Revenue
Ownership Private

Proprietary targeted protein degradation platform generating PROTAC degraders against undruggable cancer targets.
Eclipsor is Beactica Therapeutics' proprietary platform for generating proteolysis-targeting chimeras that recruit disease-causing proteins to E3 ligases for proteasomal destruction.
The platform's event-driven pharmacology enables catalytic potency at lower doses and longer duration than traditional inhibitors, and it supports allosteric modulation, protein-protein interaction inhibition, and targeted protein degradation modalities. Beactica reported in vivo validation of the platform in 2024 and uses it to build its internal oncology pipeline.
Nurix

DEL-AI Discovery Engine
nurixtx.com
Arvinas

PROTAC Discovery Engine
arvinas.com
C4 Therapeutics

TORPEDO Platform
c4therapeutics.com
Adds products that compete with one of Eclipsor’s direct competitors but not with Eclipsor itself. They are shaded, and Linked Through names the direct competitor each one competes with.
| Attribute | Eclipsor | DEL-AI Discovery Engine | PROTAC Discovery Engine | TORPEDO Platform | |
|---|---|---|---|---|---|
| Provider | |||||
| Founded | 2006 | 2012 | 2013 | 2015 | |
| Sells To | Businesses | Enterprise | Enterprise | Enterprise | |
| Pricing Model | Pre-Revenue | Recurring, Software | Recurring, Software | Recurring, Software | |
| Ownership | Private | Public | Public | Venture-backed |
Provider 
Founded 2006
Sells To Businesses
Pricing Model Pre-Revenue
Ownership Private
Provider 
Founded 2012
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2013
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Public
Provider 
Founded 2015
Sells To Enterprise
Pricing Model Recurring, Software
Ownership Venture-backed